FIRECREST Customer Support

ICON will attend the 19th EBF Open Symposium, taking place from 17–19 November at the Hyatt Regency Barcelona Tower. Join us at booth #B1 to meet our experts and learn how ICON delivers high-quality bioanalytical soluti...

Getting actionable FDA feedback starts long before your submission. A well-prepared Pre-Sub can help AI-enabled SaMD developers clarify requirements, address risks early and make the most of valuable FDA review time. L...

Biopsies remain the gold standard in MASH clinical trials, but they are far less common in everyday clinical practice. As more patients are diagnosed and managed using non-invasive tests, the gap between routine care a...

Pharmacovigilance obligations increase once a product enters the market. What worked at launch may no longer scale as products are used in the real world. ICON helps navigate this complexity with post-marketing pharmaco...

In cell and gene therapy, the unit of supply is no longer simply a vial. It is an interconnected journey involving the patient, product, place, time, condition and decision status. At IRT & RTSM 2026, ICON’s Alyssa Gill...

Latest issue out now. Regulatory requirements continue to evolve across global markets. Keeping pace with changes from the FDA, EMA, MHRA, PMDA, NMPA and other health authorities is critical for successful product deve...

ICON reports third quarter 2026 results. Sustained commercial excellence delivers net business wins in the quarter of $3,150 million; a net book-to-bill of 1.56x and closing backlog of $24.5 billion, up 4.8% sequentially...

Early intervention is the most promising path forward for MASLD, and extremely difficult to execute. Without reliable methods for identifying biologically high-risk patients before symptoms emerge, early-intervention tri...

ICON is looking forward to once again attending the #OCTDACH conference on 3–4 November at the Congress Center in Basel, Switzerland. We invite you to visit us at booth \#6 to learn how we can help you navigate complex...

On demand content for your scientific materials. Highly configurable organization and search capabilities speed your research and improve collaboration. Experience the difference it could make for you with a demo: https:...

Often, COA decisions are made too late, with endpoint selection, validation, and global deployment treated as separate activities rather than components of a single early-stage COA strategy. Join our upcoming webinar t...

Because patients can’t wait, every rare disease development decision matters. Meet ICON at World Orphan Drug Congress Europe, booth \#313, to discuss how our integrated development and regulatory strategy, patient advoca...